Maze Therapeutics, Inc. (MAZE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 15. Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on the stock and has a $28.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Buy rating due to a combination of factors, including Maze Therapeutics’ diligent execution on its platform of novel, small-molecule precision medicines targeting renal, cardiovascular, and related metabolic diseases. The company’s lead asset, MZE829, is showing promise as it continues patient enrollment in the Phase 2 HORIZON study, which targets a broad population of patients with APOL1 kidney disease. Initial proof-of-concept data for MZE829 is anticipated in early 2026, and the asset is considered differentiated due to its design to mimic a protective variant of the APOL1 gene.
Additionally, Maze’s second program, MZE782, is progressing well in its Phase 1 trial, with initial data expected by the third quarter of 2025. The company plans to initiate Phase 2 trials for chronic kidney disease and phenylketonuria based on these results. Financially, Maze is in a strong position, ending the quarter with $294.4 million in cash, which is expected to support operations into the second half of 2027. These developments, along with the upcoming catalysts, contribute to the positive outlook and the reiteration of the $28 price target for Maze’s stock.